Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Consumer OTC Drugs

Nutraquest bankruptcy

This article was originally published in The Tan Sheet

  • News

Executive Summary

Manasquan, N.J.-based firm, formerly known as Cytodyne Technologies, estimates its debt at between $50 mil. and $100 mil. and assets at $10 mil. to $50 mil. in Oct. 16 Chapter 11 filing. Filing puts federal and state lawsuits related to Cytodyne's ephedra-containing and ephedra-free Xenadrine products, including a hold on wrongful death suit filed by widow of Orioles pitcher Steve Bechler (1"The Tan Sheet" July 21, 2003, p. 3). Cytodyne President Robert Chinery formed Nutraquest in June when Cytodyne licensed rights to all its products to Xenadrine manufacturer Phoenix Labs (2"The Tan Sheet" June 23, 2003, p. 13)...

Table

View full table

Topics

Tags:
Consumer OTC Drugs
Latest Headlines

Mismatch Between Growing Vaccine Pipeline and CDC’s ACIP Capacity

Keeping Track: Two Breakthrough Oncologics, Another Antibiotic Clear US FDA Along With Pfizer’s Hemophilia B Gene Therapy

Priority Review Vouchers: Tropical Disease Candidates Wait Years For FDA Action On Qualifying List

Pink Sheet Podcast: US FDA Biosimilar Strategy, Gene Therapy Accelerated Approvals, FDA v. Partisan Politics

See All
UsernamePublicRestriction

Register

PS096096

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By